TG Therapeutics (TGTX) is trading higher as the market digests a cluster of recent, BRIUMVI-related positives rather than a single intraday headline. The setup includes a recent FDA supplement approval for BRIUMVI (ublituximab-xiiy), reinforcing regulatory momentum, alongside investor focus on the company’s 2026 growth framework.

The company’s latest outlook calls for approximately $875–$900 million in total global revenue in 2026, including about $825–$850 million in U.S. net product revenue from BRIUMVI. With BRIUMVI remaining the dominant value driver, incremental signals around durability of demand and execution against that 2026 target can move the stock even on relatively quiet news days. (ir.tgtherapeutics.com)

Beyond revenue guidance, TG recently strengthened its financial flexibility with a new five-year, $750 million senior secured credit facility. Investors have also pointed to capital return capacity, following board authorization of a $100 million share repurchase program (separate from the financing) as supportive of the equity narrative. (ir.tgtherapeutics.com)

Near-term attention is likely to stay on evidence that BRIUMVI demand can keep compounding against larger MS incumbents, and on progress toward lifecycle expansion such as the subcutaneous program. Any additional regulatory, reimbursement, or prescribing updates that sharpen confidence in the 2026 revenue path could amplify moves like today’s, while signs of slowing momentum would likely pressure the stock.